Active substance
Nabilone
- US FDA 1
- Health Canada 9
- NHS prices 2
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CESAMET | 1MG | capsule · oral | BAUSCH | Discontinued | 26 Dec 1985 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CESAMET | 00548375 | 1 MG | CAPSULE · ORAL | BAUSCH HEALTH, CANADA INC. |
| CESAMET | 02256193 | 0.5 MG | CAPSULE · ORAL | BAUSCH HEALTH, CANADA INC. |
| CESAMET | 02312263 | 0.25 MG | CAPSULE · ORAL | BAUSCH HEALTH, CANADA INC. |
| PMS-NABILONE | 02380897 | 0.25 MG | CAPSULE · ORAL | PHARMASCIENCE INC |
| PMS-NABILONE | 02380900 | 0.5 MG | CAPSULE · ORAL | PHARMASCIENCE INC |
| PMS-NABILONE | 02380919 | 1.0 MG | CAPSULE · ORAL | PHARMASCIENCE INC |
| TEVA-NABILONE | 02384884 | 0.5 MG | CAPSULE · ORAL | TEVA CANADA LIMITED |
| TEVA-NABILONE | 02384892 | 1.0 MG | CAPSULE · ORAL | TEVA CANADA LIMITED |
| TEVA-NABILONE | 02392925 | 0.25 MG | CAPSULE · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Nabilone 1mg capsules | £225.40 | 20 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Nabilone 250microgram capsules | £172.50 | 20 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.